TRACTIVUS is a spin-off from IQS and IDIBELL that develops implantable medical devices that avoids bacteria colonisation. The patented technology allows to create an autoprotection system onto the surface of each medical device that prevents bacteria attachment and bacteria colonisation. Therefore, our devices showed no bacteria colonisation and no biofilm formation increasing the lifetime of the device with no post-implantation problems and with no adverse effects for the patient.
In addition, we are offering a reduction in health costs directly related to treat post-implantation problems such as infection.
Learn All About the Advantages that Our Products & Technology Has to Offer
All selected materials showed no toxicity or inflammatory responses. Silicone and silver are commonly used by the current medical devices and complies with the approved regulations.
Our patented technology enables nanostructured material attached to the surface of the silicone surface.
The bacteriaphobic coating is adapted perfectly to the silicone geometry and shows no delamination and no cracking.
The flexibility of the technique allows to control the modification area, being possible to select the internal or external side or both sides.
The nanostructured coating allows lower interaction between the surface of the device and the mucus avoiding its attaching and aggregation.
Due to the origin and history of the project, TRACTIVUS have designed its initial portfolio based with two initial products (tracheal stent and urinary catheter). The novelty of the technology allows to be applied on different medical devices such as tubes, prosthesis, catheters and stents. While the main objective at this moment consist on the validation an approval of the two first products, TRACTIVUS is working on increasing the pipeline.
Is our primary technology that is used to give bacteriaphobic properties to the medical devices. Consist on a flexible structural coating that attaches directly to the surface of the materials (elastomeric materials and rigid materials) providing bacteriaphobic properties. This means that the surface difficult bacteria adhesion and attachment avoiding the formation of the bacteria biofilm and colonization.
New bacteriaphobic tracheal stent with PHOBOSTech. The device shows the same mechanical properties as standard devices but avoiding bacteria colonisation and biofilm formation. The device can be implanted as usual and can be identified through X-ray and fluoroscopy facilitating the implantation and following-up process.
New bacteriaphobic urinary catheter with PHOBOSTech. The device is completely flexible as standard devices but avoiding bacteria colonization and biofilm formation during the urine drainage. The product increase the lifetime of the device (>30 days) without colonisation problems reducing the infection rates.
We've Come a Long Way
Tractivus is a technology-based company, established in Barcelona in 2015 and emerged from the research groups, GEMAT (Institut Químic de Sarrià, IQS, TECNIO centre, Ramon Llull University, URL) and IDIBELL (Hospital of Bellvitge, CERCA centre, University of Barcelona).
It has been recognised with the help of Llavor 2014 (Catalan Government) for its business idea. In addition, it was awarded as 2nd finalist for the best business plan of 2014 in the BioemprenedorXXI programme, organised by Biocat (Catalan Government), Barcelona Activa (City of Barcelona) and la Caixa. We also participated in the program of entrepreneurship and acceleration of start-ups, I-CORPS, of the National Science Foundation (US Government).
Finally, the Tractivus technology was awarded at the 2015 ECBIP Congress (European Congress for Bronchology and Interventional Pulmonology) with the Chris Bollinger Award for the best technology and development in the field of tracheal stents.
We obtained funding from recognised funds as for instance NEOTEC (Ministry of Science, Innovation and Universities, Spain), StartUp Capital (Catalan Government), RIS3CAT (Catalan Government), RETOS y Colaboración (Ministry of Science, Innovation and Universities, Spain) and with private investors.
At Tractivus, we are passionate about science and we love to see how our technology meets patients’ needs and has a great impact on the society.